Abstract
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these communities might respond to these developments.
| Original language | English |
|---|---|
| Pages (from-to) | 308-310 |
| Number of pages | 3 |
| Journal | The British journal of psychiatry : the journal of mental science |
| Volume | 225 |
| Issue number | 2 |
| Early online date | 20 May 2024 |
| DOIs | |
| Publication status | Published - 1 Aug 2024 |